Study title:
Bruggers-C-S, Greene-D.
Dr. C.S. Bruggers, Division of Pediatric Hematology-Oncology, Primary
Children's Medical Center, 100 North Medical Drive, Salt Lake City, UT 84113, United States
A phase 2 feasibility study of sequential, dose intensive
chemotherapy to treat progressive low-grade gliomas in children.
Journal of Pediatric Hematology/Oncology {J-PEDIATR-HEMATOL-ONCOL},
2007, Vol/Iss/Pg. 29/9 (602-607), eISSN: 1536-3678, ISSN: 1077-4114.Bruggers-C-S, Greene-D.
Dr. C.S. Bruggers, Division of Pediatric Hematology-Oncology, Primary
Children's Medical Center, 100 North Medical Drive, Salt Lake City, UT 84113, United States
A phase 2 feasibility study of sequential, dose intensive
chemotherapy to treat progressive low-grade gliomas in children.
Jour...
Type of medicine: Medicines containing chemical active substances
|
Therapeutic area: Cardiovascular Diseases
|
Brands: Please see report |
MAH holders: Please see report |
Assessment: |
Active substance: ENALAPRIL |
ATC code: |
Document link:
|
Document date:
|
Study number: |
EudraCT number:
|
Scope of study: Clinical |
Population of study subjects:
|
Preterm newborn Infants
|
Newborn infants
(1 to 27 days)
|
Infants and toddlers
(28 days to 24 months)
|
Children
(2 to 11 years)
|
Adolescents
(12 to 18 years)
|
|
-
|
-
|
-
|
Y
|
Y
|